Over the last few decades, extensive studies by several groups have introduced the concept of cellderived secreted extracellular membrane vesicles as carriers of complex molecular information. Owing to their pleiotropic biological effects and involvement in a wide variety of biological processes, extracellular membrane vesicles have been implicated in physiological as well as pathological events, including tumour development and metastasis. In the present review, we discuss the role of secreted membrane vesicles in intercellular communication with a focus on tumour biology. Of particular interest is the potential role of extracellular vesicles as orchestrators of common features of the malignant tumour microenvironment, e.g. coagulation activation and angiogenesis.
Introduction
The preceding view of intercellular communication in mammalian organisms has been limited to direct cell-cell contact, the secretion of soluble factors activating cell-surface receptors on recipient cells and cell-matrix interactions. A vast amount of data indicates that eukaryotic cells can exchange information of high complexity associated with cellderived EMVs (extracellular membrane vesicles) (referred to in the present review as both exosomes and shed microvesicles). We now appreciate the fact that EMVs evoke biological responses through the transfer of signalling proteins and genetic material between cells [1] [2] [3] [4] . According to the present view, the formation of EMVs occurs through at least two distinct processes. Microvesicles, also termed oncosomes if derived from tumour cells, and MPs (microparticles), if derived from blood cells, are plasma-membrane-derived vesicles, 50-1000 nm in size. Exosomes are 30-150-nm-sized particles released from multivesicular bodies upon their fusion with the plasma membrane. Multivesicular bodies were originally thought to traffic extracellular molecules to lysosomes for degradation. Unexpectedly, Johnstone and colleagues found evidence of the opposite process during reticulocyte maturation, i.e. vesicular release of cargo in exosomes from multivesicular bodies fusing with the plasma membrane [5] . Notably, the mechanisms of EMV release have considerable overlap with the biogenesis and release of several viruses, suggesting a conserved system of co-dependence throughout evolution [6, 7] . Despite their different modes of formation, the molecular composition of exosomes and microvesicles demonstrate striking similarities with regard to surface proteins and cytoskeletal proteins, and the absence of organelle proteins. For example, the ESCRT (endosomal sorting complex required for transport) member Tsg101 (tumour susceptibility gene 101), found to mediate virusindependent budding from the plasma membrane, and the tetraspanin CD63, which is enriched in specific plasma membrane domains upon microvesicle budding, have both been characterized as exosomal markers. In the context of the potential utility of EMVs as biomarkers, it is notable that the composition of EMVs in general reflects their cell of origin, e.g. reticulocyte-derived vesicles contain transferrin receptors, vesicles derived from dendritic cells display MHC molecules, and glioma-cell-derived vesicles may carry the truncated variant of EGFR (epithelial growth factor receptor). In addition to protein and lipid, coding and non-coding RNA and single-stranded DNA may be present in the lumen of EMVs [1, 2, 8, 9] . Thus EMV-mediated intercellular communication includes, but is not restricted to, direct activation of cell-surface receptors on recipient cells, transfer and translation of mRNAs, transfer of miRNAs (microRNAs) and silencing of mRNA targets, transfer of functional proteins and the induction of cell signalling pathways upon their internalization. Given their release into the circulation, EMV-dependent signalling may occur not only locally, but also in a paracrine and systemic manner. From what is given above, it may be concluded that EMVs provide an attractive ligand for the demonstration of functional effects in various biological systems; however, deciphering the exact mechanisms behind descriptive data poses a great challenge.
Role of EMVs in cancer
Cancer is one of the leading causes of death in countries with a lifestyle based on smoking, high alcohol consumption and high calorie intake, combined with a high standard of living and an extensive healthcare budget (also referred to as the developed world). The specific characteristics of the tumour microenvironment and how these depend on intercellular communication of malignant cells and non-malignant cells of the host has gained increasing attention in recent years. The link between EMVs and cancer was suggested from early studies on a cell line derived from a patient with Hodgkin's disease [10] . More recently, studies have evaluated the hypothesis that cancer-cell-derived EMVs constitute an important communication pathway in the modulation of stromal cells. The transformation of fibroblasts and epithelial cells upon uptake of GBM (glioblastoma)-and breastcancer-cell-derived EMVs was partly dependent on the transfer of fibronectin and transglutaminase [11] . Furthermore, EMVs may modulate the stroma and promote metastasis by presenting several proteases, including uPA (urokinase-type plasminogen activator), MMP (matrix metalloproteinase)-2 and MMP-9. From animal studies, it has been suggested that EMVs may contribute to metastasis by priming the premetastatic niche in lymph nodes and other distant organs [12] . In a recent study, cross-talk between cancer-cell-derived EMVs and bone marrow progenitor cells was proposed; EMV-dependent transfer of the oncoprotein Met was found to be a key mediator of bone marrow education and metastatic progression [13] . Moreover, Rab27a blockade in mammary carcinoma cells was shown to attenuate the secretion of exosomes, resulting in decreased primary tumour growth and lung metastasis in mice [14] .
Role of EMVs in tumour angiogenesis
Low oxygen tension, or hypoxia, is a relatively specific and general feature of the microenvironment of malignant tumours [15] . Cancer cells induce adaptive mechanisms to cope with hypoxia that rely on phenotypic modulation of stromal cells in the neighbouring tissue and the recruitment of bone-marrow-derived progenitors from the circulation. This adaptive remodelling of the tumour microenvironment ultimately serves to promote the survival and dissemination of malignant cells, and involves the induction of a large number of effector molecules that drive, e.g., angiogenesis and protease processing of the extracellular matrix [16] . In the clinical setting, hypoxia is associated with local invasion, therapy resistance, systemic spread and poor patient prognosis in many human malignancies. Accordingly, hypoxia-induced proteins, most importantly VEGF (vascular endothelial growth factor), have provided new targets in the treatment of cancer. It has become clear from clinical studies that successful targeting of hypoxia and angiogenesis requires an increased understanding of the complex network of intercellular communication that shapes the tumour microenvironment. EMVs may promote angiogenesis owing to the fact that they contain mRNA, miRNA and angiogenic growth factors that could directly or indirectly stimulate EC (endothelial cell) function. It was suggested that EMVs released from human renal cancer stem cells stimulate angiogenesis and pre-metastatic niche formation in lung tissue [17] . Studies by others have demonstrated a role for EMVs by presenting Delta-like 4 to Notch receptors expressed by the endothelium, thereby promoting differentiation into an EC tip cell phenotype [18] , and that the transfer of mRNA derived from endothelial progenitor cells activates an angiogenic programme through the PI3K (phosphoinositide 3-kinase)/Akt pathway [19] . Although these and other studies suggest a role for EMVs in angiogenesis, EMVs as mediators of intercellular communication in the tumour microenvironment remains to be elucidated. Our group recently set out to address this question, the results of which are discussed below.
Extracellular membrane vesicles mediate coagulation-dependent hypoxic signalling in cancer
Malignant tumours are characterized by the activation of the coagulation system, and intravascular thrombosis exacerbates intratumoral hypoxia, abnormal angiogenesis and tumour necrosis [20, 21] . The hypercoagulative activity of malignant tumours is largely related to the overexpression of TF (tissue factor), i.e. a 47 kDa plasma-membraneintercalated glycoprotein that serves as the major initiator of the coagulation cascade [20, 21] . Experimental models of tumour development as well as human cancer materials link TF to the aggressiveness of several malignancies, including GBM [22] . Several reports have suggested that TF may be triggered by hypoxia in cancer cells [23] , and one may envisage a vicious cycle of hypoxia, abnormal angiogenesis and coagulation activation that drives the invasiveness and metastatic behaviour of malignant tumours [24] . TF, as an alternatively spliced variant [25] or as part of platelet-derived MPs, has been suggested to circulate at increased levels in patients with tumour types associated with high risk of VTE (venous thromboembolism). It was demonstrated that circulating TF-positive MPs in patients with an underlying malignancy displayed pro-coagulative capacity [26] , and platelet-derived MPs may display up to 100-fold higher specific pro-coagulant activity compared with activated platelets [27] . Emission of TF-bearing MPs into the circulation may thus serve as a vehicle for the wellknown systemic coagulopathy in cancer patients [28, 29] .
Apart from being involved in the end stages of coagulation, TF also mediates coagulation-independent signalling through a specific class of G-protein-coupled receptors, i.e. PARs (protease-activated receptors) (Figure 1 ). TF-dependent PAR-2 signalling has been specifically associated with angiogenesis in physiological models as well as in tumours [20, 30] . We have found that hypoxia induces a dramatic increase in TF in GBM-cell-derived EMVs [31] . GBM tumours are highly aggressive brain tumours characterized by hypoxia, hypercoagulation, necrosis and a vascular density that is among the highest of all human malignancies [32] . We demonstrated further that TF-bearing EMVs mediate paracrine activation of hypoxic ECs through PAR-2 signalling. At a mechanistic level, ERK1/2 (extracellularsignal-regulated kinase 1/2)-dependent up-regulation of the potent pro-angiogenic factor HB-EGF (heparin-binding epidermal growth factor-like growth factor) effectuated EC activation downstream of PAR-2. It is tempting to speculate that tumour-cell-derived TF-enriched EMVs may provide a non-invasive marker that reflects tumour aggressiveness, and that may be used as a predictive marker of tumour progression or treatment response. Of particular interest in the context of our results, others have shown that EMVs can transfer the oncogenic form of EGFR, EGFRvIII, between GBM cells [33] as well as from GBM cells to ECs [34] , resulting in EGFRvIII-driven phenotypic modulation of recipient cells. Given the capability of EMVs to transfer functional proteins between cells, an interesting idea for future studies would be the potential transfer of functional TF from cancer-cell-derived EMVs to ECs that normally lack TF. This would render hypoxic ECs independent of external stimuli for the support of tumour angiogenesis through PAR-2. Also related to our studies, it was shown that hypoxic GBM cells display increased TF-mediated PAR-2 activation [35] , and that EGFRvIII-transformed GBM cells become hypersensitive to TF/PAR-mediated signalling [36] . Whereas malignant transformation of cancer cells may induce TF as well as PARs, our findings suggest that hypoxia specifically up-regulates TF in cancer cells, whereas PAR expression is rather down-regulated. In contrast, hypoxia was found to specifically up-regulate PAR-2 in ECs, whereas, unexpectedly, TF was absent even after prolonged exposure to hypoxic conditions [31] . Together, the findings by our group and others thus point to a complex interaction between oncogenic events and non-oncogenic events in coagulation-dependent signalling mediated by EMVs in the tumour microenvironment.
Concluding remarks
Given the release of EMVs into various body fluids and the fact that their composition frequently reflects their tissue of origin, the clinical use of EMVs in terms of diagnostic biomarkers and predictors of treatment response emerge as a promising possibility; however, the dynamics of EMV stability and clearance in various tissues or in the circulation are currently unknown and need further investigation. Moreover, the stability of EMV-associated RNA and protein in serum and plasma during freezing and thawing is still a matter of debate, and the clinical implementation of EMVs as biomarkers will depend on studies that convincingly establish the utility of EMV analyses on archived samples. On a functional level, a direct demonstration of tumour-promoting effects of EMVs in cancer patients is still lacking, both locally in the tumour as well as at the systemic level. Such studies will probably require a better understanding of how the EMV machinery could be targeted pharmacologically and/or how to target ligand-receptor interactions involved in the uptake of EMV cargo. Regarding the transfer of RNAs [37] , it remains an enigma how these highly polyanionic macromolecules escape from internalized EMVs, which supposedly are enclosed in endocytic vesicles of recipient cells, and how they gain access to their destination of action. An increased understanding of these events will also be important in the context of EMVs as drug-delivery vehicles, which is yet another interesting branch of this exciting field of research.
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